Scott Bizily
About Scott Bizily
Scott Bizily, J.D., Ph.D., is Chief Legal Officer and Corporate Secretary of 4D Molecular Therapeutics (FDMT). He has served as CLO since September 2021 and also served as Chief Human Resources Officer from June 2022 to January 2024. He is 53 years old as of April 29, 2025, and holds a B.A. in Ecology & Evolutionary Biology (Princeton, 1994), a Ph.D. in Genetics (University of Georgia, 2001), and a J.D. (University of Pennsylvania Carey Law School, 2005). Prior roles include General Counsel at Synthego (2019–2021), Director/Corporate Counsel at BioMarin (2010–2019), patent litigation at Weil, Gotshal & Manges (2005–2007), life sciences licensing at Cooley (2007–2009), and a postdoctoral fellowship at the University of Pennsylvania (2001–2002). Company proxies do not disclose his individual TSR, revenue, or EBITDA performance metrics.
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| 4D Molecular Therapeutics | Chief Legal Officer; Corporate Secretary | Sep 2021–present | Senior legal leadership; corporate governance signatory (e.g., bylaws and 8-K signatures) |
| 4D Molecular Therapeutics | Chief Human Resources Officer | Jun 2022–Jan 2024 | Oversaw HR during transition period |
| Synthego Corporation | General Counsel | 2019–2021 | Led legal function at genome engineering firm |
| BioMarin Pharmaceutical Inc. | Director/Corporate Counsel | 2010–2019 | Corporate legal roles at rare disease biopharma |
| Cooley (Godward Kronish) LLP | Life sciences licensing, corporate partnering | 2007–2009 | Transactions/licensing in life sciences |
| Weil, Gotshal & Manges LLP | Patent litigation | 2005–2007 | IP litigation practice |
| University of Pennsylvania | Postdoctoral fellow | 2001–2002 | Genetics research |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Not disclosed in FDMT proxy biographies | — | — | No public company directorships or committee roles are mentioned in 2023–2025 proxy executive bios. |
Fixed Compensation
| Year | Base Salary ($) | Target Bonus (%) | Actual Bonus Paid ($) |
|---|---|---|---|
| 2022 | Not disclosed (not a named executive officer) | Not disclosed | Not disclosed |
| 2023 | Not disclosed (NEOs were CEO, COO, CMO) | Not disclosed | Not disclosed |
| 2024 | Not disclosed (NEOs were CEO, CFO, COO) | Not disclosed | Not disclosed |
FDMT proxies do not include Bizily in the Summary Compensation Tables for 2022–2024; therefore, his base salary, target bonus, and actual bonus are not disclosed. The company uses an annual performance-based cash bonus program for executives, but specific targets for Bizily are not provided.
Performance Compensation
| Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|
| Company annual bonus program (design reference) | For NEOs: CEO 100% corporate; others 90% corporate/10% individual (2022 design) | Corporate goals (product development and business objectives) | Board assessed 2022 corporate performance at 110% (NEO reference) | NEO bonuses paid per SCT; Bizily-specific outcomes not disclosed | Equity awards typically vest monthly over 4 years for options granted (NEO reference) |
Notes: FDMT describes executive bonus design and vesting mechanics in proxies focused on NEOs; Bizily-specific performance metrics, targets, and payouts are not disclosed.
Equity Ownership & Alignment
- Beneficial ownership: FDMT’s 2024–2025 security ownership tables highlight major holders and specific insiders (e.g., CEO), but do not provide an individual beneficial ownership line for Bizily; his holdings are therefore not disclosed in those tables.
- Section 16 compliance: FDMT reports a minor delinquency—Bizily filed a Form 4 due on June 5, 2023 on June 6, 2023. This confirms he had at least one reportable insider transaction in 2023.
- Hedging/Pledging: FDMT prohibits hedging transactions for officers and directors (e.g., zero-cost collars, forward sales). The proxy excerpt addresses hedging and insider trading policy; pledging is not expressly referenced in the excerpt provided.
- Ownership guidelines: No executive stock ownership guideline disclosure for Bizily is included in the proxy excerpts reviewed.
Employment Terms
- Employment status: At-will employment language is standard in FDMT’s change-in-control severance agreements; Bizily’s specific offer letter/severance terms are not disclosed in the filings reviewed.
- Change-in-control/severance framework (NEO reference): Outside CoC period—9 months base salary, pro‑rated target bonus, prior-year unpaid bonus, and up to 9 months COBRA for non-CEO NEOs; During CoC period—12 months base salary, 12 months plus pro‑rated target bonus, prior-year unpaid bonus, up to 12 months COBRA, and full equity vesting acceleration (except performance-vesting awards). CEO multiples are higher. Bizily’s agreement terms are not disclosed; this reflects NEO framework only.
- Indemnification: FDMT uses standard indemnification agreements for directors and executive officers.
Investment Implications
- Compensation transparency risk: Bizily is not a named executive officer in the 2022–2024 proxies, limiting visibility into his cash/equity mix, bonus targets, and vesting—reducing pay-for-performance clarity for this role.
- Insider activity signal: A minor Section 16 filing delinquency (one-day late Form 4 in June 2023) indicates at least one reportable transaction; without Form 4 details, it does not by itself imply selling pressure.
- Alignment safeguards: Hedging is prohibited for officers and directors, supporting alignment and reducing risk of adverse hedging strategies; pledging status is not specified in the excerpt provided.
- Retention and governance: Tenure since 2021 and ongoing role as Corporate Secretary/signatory on governance filings (e.g., amended bylaws, 8-K signatures) suggest integration into core governance functions; absence of disclosed severance specifics for Bizily makes retention economics opaque relative to NEO frameworks.